Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access for CC-10004

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03740516
Expanded Access Status : No longer available
First Posted : November 14, 2018
Last Update Posted : April 29, 2020
Sponsor:
Information provided by (Responsible Party):
Amgen

Brief Summary:
This is an expanded access program (EAP) for eligible participants designed to provide access to CC-10004.

Condition or disease Intervention/treatment
Bechet's Disease Drug: CC-10004

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Expanded Access for CC-10004

Resource links provided by the National Library of Medicine

Drug Information available for: Apremilast


Intervention Details:
  • Drug: CC-10004
    CC-10004 will be administered orally
    Other Name: Apremilast, Otezla

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

-

Exclusion Criteria:

-


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03740516


Locations
Layout table for location information
United States, New Jersey
Celgene
Summit, New Jersey, United States, 07901
Sponsors and Collaborators
Amgen
Investigators
Layout table for investigator information
Study Director: MD Amgen
Layout table for additonal information
Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT03740516    
Other Study ID Numbers: CC-10004
First Posted: November 14, 2018    Key Record Dates
Last Update Posted: April 29, 2020
Last Verified: April 2020
Keywords provided by Amgen:
Expanded Access
Compassionate Use
Additional relevant MeSH terms:
Layout table for MeSH terms
Apremilast
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents